NZ628828A - Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease - Google Patents

Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease

Info

Publication number
NZ628828A
NZ628828A NZ628828A NZ62882813A NZ628828A NZ 628828 A NZ628828 A NZ 628828A NZ 628828 A NZ628828 A NZ 628828A NZ 62882813 A NZ62882813 A NZ 62882813A NZ 628828 A NZ628828 A NZ 628828A
Authority
NZ
New Zealand
Prior art keywords
prevention
pharmaceutical composition
treatment
liver disease
fatty liver
Prior art date
Application number
NZ628828A
Other languages
English (en)
Inventor
Se Chang Kwon
Sung Hee Park
Se Young Lim
Ryoung Ae Shin
In Young Choi
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of NZ628828A publication Critical patent/NZ628828A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ628828A 2012-03-09 2013-03-08 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease NZ628828A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120024632A KR101665009B1 (ko) 2012-03-09 2012-03-09 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
PCT/KR2013/001897 WO2013133667A1 (en) 2012-03-09 2013-03-08 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
NZ628828A true NZ628828A (en) 2016-09-30

Family

ID=49117073

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628828A NZ628828A (en) 2012-03-09 2013-03-08 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease

Country Status (25)

Country Link
US (1) US20150056223A1 (enExample)
EP (1) EP2838549B1 (enExample)
JP (4) JP2015510880A (enExample)
KR (1) KR101665009B1 (enExample)
CN (2) CN110075277A (enExample)
AR (1) AR090287A1 (enExample)
AU (1) AU2013228152C1 (enExample)
CA (1) CA2864250C (enExample)
DK (1) DK2838549T3 (enExample)
ES (1) ES2900823T3 (enExample)
HK (1) HK1199220A1 (enExample)
HU (1) HUE057245T2 (enExample)
IL (1) IL234133B (enExample)
IN (1) IN2014DN06694A (enExample)
MX (2) MX2014010542A (enExample)
MY (1) MY167214A (enExample)
NZ (1) NZ628828A (enExample)
PH (1) PH12014501785B1 (enExample)
PL (1) PL2838549T3 (enExample)
PT (1) PT2838549T (enExample)
RU (1) RU2635966C2 (enExample)
SG (1) SG11201404733UA (enExample)
TW (2) TWI658835B (enExample)
WO (1) WO2013133667A1 (enExample)
ZA (1) ZA201405918B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2721062T1 (sl) 2011-06-17 2019-03-29 Hanmi Science Co., Ltd. Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
US9724420B2 (en) 2012-11-06 2017-08-08 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region
MX369656B (es) 2014-01-20 2019-11-15 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma.
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI802396B (zh) * 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
CR20180034A (es) * 2015-06-30 2018-04-16 Hanmi Pharm Ind Co Ltd Derivados de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
EP4534107A3 (en) * 2015-09-24 2025-12-10 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
EP3384935A4 (en) * 2015-12-02 2019-08-21 Hanmi Pharm. Co., Ltd. PROTEIN COMPLEX WITH FATTY ACID DERIVATIVE AND MANUFACTURING METHOD THEREFOR
AU2017332408B2 (en) 2016-09-23 2022-02-10 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
KR101906333B1 (ko) 2016-12-07 2018-10-11 고려대학교 산학협력단 지방간의 진단 또는 치료를 위한 류신 지퍼 단백질의 용도
KR101964743B1 (ko) 2017-01-19 2019-08-14 울산대학교 산학협력단 Gnpat을 유효성분으로 포함하는 비알콜성 지방간염 진단용 또는 치료 예후 예측용 바이오마커 조성물
AU2018239037B2 (en) 2017-03-23 2022-05-26 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
EP3437651A1 (en) * 2017-08-03 2019-02-06 Université de Strasbourg Peptides for treatment and prevention of nonalcoholic fatty liver disease
KR102174436B1 (ko) * 2017-08-17 2020-11-04 주식회사 엘지화학 불용성 안료 화합물의 정성분석방법
KR20200135618A (ko) 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
EP3823659A4 (en) * 2018-07-19 2022-06-22 D&D Pharmatech Inc. PHARMACEUTICAL COMPOSITION WITH A POLYPEPTIDE
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN110151980B (zh) * 2019-06-30 2022-12-09 中国药科大学 Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
KR102315866B1 (ko) * 2020-03-24 2021-10-21 한국원자력의학원 섬유화 질환 복합 치료제 개발

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
KR101135244B1 (ko) * 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
CA2545023A1 (en) * 2003-11-25 2005-06-09 Novo Nordisk A/S Novel salicylic anilides
WO2007022518A2 (en) * 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20100033010A1 (en) * 2007-03-06 2010-02-11 Bridgestone Corporation Rubber track
US8249718B2 (en) * 2008-07-11 2012-08-21 Medtronic, Inc. Programming posture state-responsive therapy with nominal therapy parameters
KR101200659B1 (ko) 2008-07-23 2012-11-12 한미사이언스 주식회사 세 말단 반응기를 갖는 비펩타이드성 중합체를 이용한 생리활성 폴리펩타이드 약물 결합체
EP2248449A1 (en) * 2009-05-08 2010-11-10 Koninklijke Philips Electronics N.V. Kitchen appliance
WO2011109787A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물

Also Published As

Publication number Publication date
JP2022025114A (ja) 2022-02-09
ES2900823T3 (es) 2022-03-18
JP2019214627A (ja) 2019-12-19
AU2013228152C1 (en) 2017-11-23
KR20130103190A (ko) 2013-09-23
RU2014133615A (ru) 2016-04-27
PT2838549T (pt) 2021-12-31
HK1199220A1 (en) 2015-06-26
AR090287A1 (es) 2014-11-05
PL2838549T3 (pl) 2022-02-14
JP2018009022A (ja) 2018-01-18
CN104159597A (zh) 2014-11-19
ZA201405918B (en) 2015-08-26
EP2838549B1 (en) 2021-09-22
PH12014501785A1 (en) 2014-11-17
DK2838549T3 (da) 2022-01-03
MY167214A (en) 2018-08-14
IN2014DN06694A (enExample) 2015-05-22
PH12014501785B1 (en) 2014-11-17
TW201919688A (zh) 2019-06-01
RU2635966C2 (ru) 2017-11-17
US20150056223A1 (en) 2015-02-26
CA2864250C (en) 2022-08-16
AU2013228152B2 (en) 2017-08-10
KR101665009B1 (ko) 2016-10-11
CN110075277A (zh) 2019-08-02
SG11201404733UA (en) 2014-09-26
MX2020001697A (es) 2020-03-20
CA2864250A1 (en) 2013-09-12
EP2838549A4 (en) 2015-12-23
TW201340981A (zh) 2013-10-16
IL234133B (en) 2020-09-30
JP2015510880A (ja) 2015-04-13
MX2014010542A (es) 2014-12-05
AU2013228152A1 (en) 2014-09-04
TWI658835B (zh) 2019-05-11
HUE057245T2 (hu) 2022-04-28
EP2838549A1 (en) 2015-02-25
WO2013133667A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
NZ628828A (en) Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
AR086660A1 (es) Composicion para el tratamiento de diabetes que comprende un conjugado de insulina de accion prolongada y conjugado de un peptido insulinotropico de accion prolongada
NZ603050A (en) An insulin conjugate using an immunoglobulin fragment
AR126851A2 (es) Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas
IL274106B2 (en) The composition containing an oxyntomodulin derivative for the treatment of hyperlipidemia
NZ585314A (en) A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
IN2012DN00407A (enExample)
JP2015536943A5 (enExample)
JP2015524427A5 (enExample)
MY161432A (en) Absorbent article
WO2012166923A3 (en) Drug loaded polymeric nanoparticles and methods of making and using same
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
AR080993A1 (es) Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
CA2902372C (en) Polymer conjugate for delivery of a bioactive agent
JP2015510880A5 (enExample)
MX2009005444A (es) Sistema de suministro para un farmaco hidrofilico no esteroide no ionizado.
AR081755A1 (es) Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
TN2013000267A1 (en) Biodegradable drug delivery compositions
WO2012022478A3 (en) Filler composition comprising beta-glucans
WO2011126839A3 (en) Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
SG194175A1 (en) Polymer conjugated prostaglandin analogues
WO2010117248A3 (ko) 피에이치 민감성 그라프트 공중합체, 이의 제조방법 및 이를 이용한 고분자 마이셀
BR112012029171A2 (pt) composição farmacêutica de ibruprofeno para injeção
AR082032A1 (es) Complejo de factor viia en el que se utiliza un fragmento de inmunoglobulina
WO2011070436A3 (en) In situ cross linked biodegradable gel with hydrophobic pockets

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2018 BY FB RICE

Effective date: 20170106

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2019 BY CPA GLOBAL

Effective date: 20180125

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2020 BY CPA GLOBAL

Effective date: 20190124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2021 BY CPA GLOBAL

Effective date: 20200123

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2022 BY MARKPRO GLOBAL COMPANY

Effective date: 20210112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2023 BY MARKPRO GLOBAL COMPANY

Effective date: 20220113

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2024 BY MARKPRO GLOBAL COMPANY

Effective date: 20230118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2025 BY MARKPRO GLOBAL COMPANY

Effective date: 20240112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2026 BY MARKPRO GLOBAL COMPANY

Effective date: 20250121